Arjo's Q3 Falls Short Despite Strong Demand and Growth Initiatives
Photo by Navy Medicine on Unsplash
Arjo's third-quarter results missed analyst expectations due to lower-than-anticipated organic growth of 3.8 percent and failure to meet adjusted EBITDA targets. However, acting CEO Niclas Sjöswärd noted growth in most markets, a significant rise in adjusted operating profit, and the successful launch of the Maxi Move 5 floor lift with over 600 units sold.
Key takeaways
- Arjo's third-quarter results fell short of analyst expectations, according to a report in Medtech Magazine, despite consistent demand for the company's medical technology solutions
- The company reported organic growth of 3
- 8 percent, underperforming the anticipated 5
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Verified mention available
Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.